Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Crinetics Pharmaceuticals

NASDAQ CRNX
$51.91 1.42 2.74%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 23 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

3.75B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
3.70B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.25
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
72.29M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
45.90 %

Upcoming events Crinetics Pharmaceuticals

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Crinetics Pharmaceuticals

Stock analysis Crinetics Pharmaceuticals

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-15.94 28.42
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
6.96 4.33
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-14.96 9.95
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.20 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-26.91 7.67

Price change Crinetics Pharmaceuticals per year

11.61$ 25.50$
Min Max

Summary analysis Crinetics Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Crinetics Pharmaceuticals

Revenue and net income Crinetics Pharmaceuticals

All parameters

Stock news Crinetics Pharmaceuticals

All news
19 December 2023 в 19:35

Crinetics Pharmaceuticals Shares Rise 13% on Carcinoid Syndrome Treatment Trial

19 December 2023 в 19:35

Crinetics Pharmaceuticals Shares Rise 13% on Carcinoid Syndrome Treatment Trial

12 September 2023 в 22:00

Crinetics Pharmaceuticals Shares Rise 17% After Soaring Monday

12 September 2023 в 21:55

Crinetics Pharmaceuticals Shares Rise 17% After Soaring Monday

11 September 2023 в 15:10

Crinetics Pharmaceuticals shares surge 65%, analysts raise price target after acromegaly treatment results

31 August 2023 в 15:10

Crinetics Pharmaceuticals shares rise as analysts see ‘drug hunters in their zone’

31 March 2022 в 19:55

Crinetics Pharmaceuticals Shares Rise 14% on Topline Results for CRN04777

31 March 2022 в 19:55

Crinetics Pharmaceuticals Shares Rise 14% on Topline Results for CRN04777

23 November 2021 в 14:30

Crinetics Pharmaceuticals started at outperform with $68 stock price target at Evercore ISI

About company Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Address:
Building No. 2, San Diego, CA, United States, 92121
Company name: Crinetics Pharmaceuticals
Issuer ticker: CRNX
ISIN: US22663K1079
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2018-07-18
Sector: Healthcare
Industry: Biotechnology
Site: https://www.crinetics.com

On which stock exchange are Crinetics Pharmaceuticals (CRNX) stocks traded?

Crinetics Pharmaceuticals (CRNX) stocks are traded on NASDAQ.

What is the ticker of Crinetics Pharmaceuticals stocks (CRNX)?

The stock ticker of Crinetics Pharmaceuticals’s stocks or in other words, the code is CRNX. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Crinetics Pharmaceuticals (CRNX) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Crinetics Pharmaceuticals (CRNX) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Crinetics Pharmaceuticals (CRNX) stocks traded?

Crinetics Pharmaceuticals (CRNX) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Crinetics Pharmaceuticals (CRNX) stocks today?

The current price of Crinetics Pharmaceuticals stocks on 17.05.2024 is 51.91 dollars. per share.

What is the dynamics of Crinetics Pharmaceuticals (CRNX) stocks from the beginning of the year?

Crinetics Pharmaceuticals (CRNX) quotes have increased by 46.68% from the beginning of the year up to 51.91 dollars. per 1 stocks.

How much did Crinetics Pharmaceuticals (CRNX) stocks increase in мае 2024?

This month Crinetics Pharmaceuticals (CRNX) quotes have increased by 15.23% to 51.91 dollars. per share.

How much are Crinetics Pharmaceuticals (CRNX) stocks worth?

Today, on October, 17.05.2024 Crinetics Pharmaceuticals’s (CRNX) stocks cost 51.91 dollars..

What is the market capitalization of Crinetics Pharmaceuticals (CRNX)?

Capitalization is the market value of Crinetics Pharmaceuticals (CRNX) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 17.05.2024, the market capitalization of Crinetics Pharmaceuticals (CRNX) is estimated at about 3752521990 dollars.